The Atlantic Meridional Overturning Circulation (AMOC) is the system of currents responsible for shuttling warm water ...
Audacy on MSN
Chicagoans continue to celebrate Kwanzaa
Hosting Kwanzaa celebrations for more than 20 years, Malcolm X College continues to honor African heritage and culture during ...
This is a story about a missing painting, from an artist you may never have heard of. Though she helped shape European modern ...
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
And now more cities are implementing curbside composting to help them meet their sustainability goals. New York is currently rolling out a mandatory composting program that will soon be effect in ...
Vor Biopharma Inc. (VOR) stock jumped to a high of $12 yesterday, gaining >20%, but as I discovered to my detriment recently, all is not exactly what it seems at the company. In this post I revisit a ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback